KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer

BACKGROUND: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are restricted to KRAS wild-type (WT) metastatic colorectal cancers (mCRCs), usually identified by direct sequencing, that may yield false negative results because of genetic heterogeneity within the tumour. We evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Malapelle, U, Carlomagno, C, Salatiello, M, De Stefano, A, De Luca, C, Bianco, R, Marciano, R, Cimminiello, C, Bellevicine, C, De Placido, S, Troncone, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419946/
https://www.ncbi.nlm.nih.gov/pubmed/22805329
http://dx.doi.org/10.1038/bjc.2012.275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419946/
https://www.ncbi.nlm.nih.gov/pubmed/22805329
http://dx.doi.org/10.1038/bjc.2012.275

Ejemplares similares